ETHINYL ESTRADIOL; NORELGESTROMIN - Generic Drug Details

What are the generic sources for ethinyl estradiol; norelgestromin and what is the scope of freedom to operate?

Ethinyl estradiol; norelgestromin is the generic ingredient in four branded drugs marketed by Amneal, Zydus Pharms, Teva Pharms Usa, Janssen Pharms, and Mylan Technologies, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Eight suppliers are listed for this compound.

Summary for ETHINYL ESTRADIOL; NORELGESTROMIN

US Patents:	0
Tradenames:	4
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	8
Clinical Trials:	21
DailyMed Link:	ETHINYL ESTRADIOL; NORELGESTROMIN at DailyMed

Recent Clinical Trials for ETHINYL ESTRADIOL; NORELGESTROMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chulalongkorn University	PHASE2
Mylan Inc.	Phase 3
Mylan Technologies Inc.	Phase 3

See all ETHINYL ESTRADIOL; NORELGESTROMIN clinical trials

Pharmacology for ETHINYL ESTRADIOL; NORELGESTROMIN

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ETHINYL ESTRADIOL; NORELGESTROMIN

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; NORELGESTROMIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORTHO EVRA	Transdermal System	ethinyl estradiol; norelgestromin	0.15 mg/0.02 mg per 24 hours	021180	1	2007-03-22

US Patents and Regulatory Information for ETHINYL ESTRADIOL; NORELGESTROMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ORTHO EVRA	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	021180-001	Nov 20, 2001		DISCN	Yes	No
Teva Pharms Usa	ONSURA	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	213977-001	Aug 25, 2021	AB	RX	No	No
Amneal	ETHINYL ESTRADIOL AND NORELGESTROMIN	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	213950-001	Feb 25, 2021	AB	RX	No	No
Mylan Technologies	XULANE	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	200910-001	Apr 16, 2014	AB	RX	No	Yes
Zydus Pharms	ETHINYL ESTRADIOL AND NORELGESTROMIN	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	214594-001	Sep 14, 2023	AB	RX	No	No

Expired US Patents for ETHINYL ESTRADIOL; NORELGESTROMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ORTHO EVRA	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	021180-001	Nov 20, 2001	5,876,746
Janssen Pharms	ORTHO EVRA	ethinyl estradiol; norelgestromin	FILM, EXTENDED RELEASE;TRANSDERMAL	021180-001	Nov 20, 2001	5,972,377

EU/EMA Drug Approvals for ETHINYL ESTRADIOL; NORELGESTROMIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gedeon Richter Plc.	Evra	norelgestromin, ethinyl estradiol	EMEA/H/C/000410Female contraception.Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.	Authorised	no	no	no	2002-08-22

Market Dynamics and Financial Trajectory for Ethinyl Estradiol; Norelgestromin

Last updated: February 21, 2026

What is the Current Market Size and Demand for Ethinyl Estradiol; Norelgestromin?

Ethinyl estradiol with norelgestromin is a combined oral contraceptive. The global contraceptive market was valued at approximately USD 22 billion in 2022.[1] The combined oral contraceptive segment accounts for a significant portion, driven by demand across developed and emerging markets. In 2022, the demand for hormone-based contraceptives increased annually by roughly 3-5%, reflecting broader reproductive health trends and rising awareness.

Key players in the market include Pfizer, Bayer, and Teva Pharmaceuticals, with several generic manufacturers entering the space as patents expire.

How Do Regulatory and Patent Dynamics Shape Market Potential?

Patent Expiry and Generic Competition

Many formulations of ethinyl estradiol and norelgestromin have faced patent expiry over the past five years, stimulating generic entry. The expiration of branded patents fosters price reductions but expands access.

Regulatory Environment

Approval procedures for oral contraceptives vary by region, with stringent requirements in the U.S. FDA and European EMA. The recent approval of biosimilar-like formulations, such as low-dose combinations, influences market composition.

Market Entry Barriers

High regulatory costs, intellectual property rights, and established brand loyalty challenge new entrants. Nonetheless, emerging markets with less mature regulations present opportunities for generic and biosimilar versions.

What is the Revenue Forecast for Ethinyl Estradiol; Norelgestromin Formulations?

Projected Growth Rates

Analysts project a compound annual growth rate (CAGR) of approximately 3.2% for the combined oral contraceptive segment through 2028.[2] The U.S. remains the largest individual market, accounting for roughly 40% of global sales.

Revenue Estimates

• 2023: Estimated USD 8.5 billion in sales worldwide.
• 2028: Forecasted to reach USD 10.2 billion.

Generic versions are expected to capture an increasing share, reducing average selling prices. Branded formulations may retain premium pricing through added benefits or formulation advantages.

Factors Affecting Revenue Trajectory

Pricing strategies, patent litigation, regional regulatory approvals, and healthcare policies heavily influence revenue prospects. Subsidies or governmental family planning programs in emerging economies can also accelerate sales volume growth.

How Do Competitive and Technological Trends Impact Market Share?

Competitive Landscape

The market is highly fragmented, with top five players controlling roughly 75% of sales. Market share shifts occur primarily due to patent cliffs, with generic companies expanding rapidly.

Technological Advances

Development of low-dose, extended-cycle, and simplified dosing regimens attracts consumer preferences. Innovations in delivery systems, such as transdermal patches or vaginal rings, offer alternative contraceptive methods but compete with oral pills.

Regulatory Innovation

Revisions to approval processes for combination pills and introduction of over-the-counter (OTC) options in select markets can increase accessibility, impacting market dynamics.

What Are the Risks and Opportunities in the Market?

Risks

• Stringent regulatory hurdles delaying product approval.
• Patent litigation delaying generic market entry.
• Changing reproductive health policies restricting access.

Opportunities

• Growth in emerging markets due to population expansion.
• Expansion of generic manufacturing to capitalize on patent expiries.
• Adoption of digital health initiatives improving prescribing trends.

Summary Table

Aspect	Data/Insight
Market Size 2022	USD 22 billion
CAGR (2023-2028)	3.2%
2023 Revenue Estimate	USD 8.5 billion
2028 Projected Revenue	USD 10.2 billion
Major Players	Pfizer, Bayer, Teva
Patent Expiry Impact	Increased generics entry presented in 2018–2022
Key Risks	Regulatory delays, patent disputes, policy restrictions
Key Opportunities	Market growth in Africa, Asia; OTC conversion potential

Key Takeaways

• The contraceptive market for ethinyl estradiol and norelgestromin is expanding modestly, driven by generics, emerging market growth, and formulary innovations.
• Patent expiries significantly affect competition, favoring generic manufacturers.
• Revenue growth is constrained by price competition but is supported by increasing consumption.
• Regulatory and policy environments are pivotal; changes can accelerate or hinder market entry.
• Technological development favors lower-dose, more convenient delivery forms, diversifying market options.

FAQs

Q1: How long do patents typically last for contraceptive formulations?
A: Approximately 20 years from the filing date, though extensions or regulatory data exclusivity can vary.

Q2: What regions hold the highest growth potential?
A: Africa and Southeast Asia show increased demand due to demographic trends and expanding healthcare infrastructure.

Q3: How do regulatory policies influence the approval of new contraceptives?
A: Stringent safety and efficacy standards can delay approvals, while regulatory streamlining in some regions can facilitate market entry.

Q4: Are non-oral contraceptives impacting the market?
A: Yes, alternatives like patches and vaginal rings are increasing adoption but still represent a smaller segment compared to oral pills.

Q5: What is the outlook for over-the-counter sales of combined oral contraceptives?
A: Several markets, including certain U.S. states, are considering OTC switches, which could significantly increase sales volume.

---

References

[1] Grand View Research. (2023). Contraceptive Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/contraceptive-market

[2] MarketsandMarkets. (2022). Oral Contraceptives Market by Type, Application, and Region. Retrieved from https://www.marketsandmarkets.com/Market-Reports/oral-contraceptive-market-245967194.html